Literature DB >> 21341268

Human embryonic stem cells rapidly take up and then clear exogenous human and animal prions in vitro.

Zuzana Krejciova1, Steve Pells, Enrico Cancellotti, Paz Freile, Matthew Bishop, Kay Samuel, G Robin Barclay, James W Ironside, Jean C Manson, Marc L Turner, Paul De Sousa, Mark W Head.   

Abstract

Susceptibility to prion infection involves interplay between the prion strain and host genetics, but expression of the host-encoded cellular prion protein is a known prerequisite. Here we consider human embryonic stem cell (hESC) susceptibility by characterizing the genetics and expression of the normal cellular prion protein and by examining their response to acute prion exposure. Seven hESC lines were tested for their prion protein gene codon 129 genotype and this was found to broadly reflect that of the normal population. hESCs expressed prion protein mRNA, but only low levels of prion protein accumulated in self-renewing populations. Following undirected differentiation, up-regulation of prion protein expression occurred in each of the major embryonic lineages. Self-renewing populations of hESCs were challenged with infectious human and animal prions. The exposed cells rapidly and extensively took up this material, but when the infectious source was removed the level and extent of intracellular disease-associated prion protein fell rapidly. In the absence of a sufficiently sensitive test for prions to screen therapeutic cells, and given the continued use of poorly characterized human and animal bioproducts during hESC derivation and cultivation, the finding that hESCs rapidly take up and process abnormal prion protein is provocative and merits further investigation.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21341268     DOI: 10.1002/path.2832

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

1.  A specific population of abnormal prion protein aggregates is preferentially taken up by cells and disaggregated in a strain-dependent manner.

Authors:  Young Pyo Choi; Suzette A Priola
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

Review 2.  The prion protein family: a view from the placenta.

Authors:  Samira Makzhami; Bruno Passet; Sophie Halliez; Johan Castille; Katayoun Moazami-Goudarzi; Amandine Duchesne; Marthe Vilotte; Hubert Laude; Sophie Mouillet-Richard; Vincent Béringue; Daniel Vaiman; Jean-Luc Vilotte
Journal:  Front Cell Dev Biol       Date:  2014-08-08

3.  Human stem cell-derived astrocytes replicate human prions in a PRNP genotype-dependent manner.

Authors:  Zuzana Krejciova; James Alibhai; Chen Zhao; Robert Krencik; Nina M Rzechorzek; Erik M Ullian; Jean Manson; James W Ironside; Mark W Head; Siddharthan Chandran
Journal:  J Exp Med       Date:  2017-11-15       Impact factor: 14.307

Review 4.  All the Same? The Secret Life of Prion Strains within Their Target Cells.

Authors:  Ina M Vorberg
Journal:  Viruses       Date:  2019-04-09       Impact factor: 5.048

Review 5.  Renewed assessment of the risk of emergent advanced cell therapies to transmit neuroproteinopathies.

Authors:  Paul A De Sousa; Diane Ritchie; Alison Green; Siddharthan Chandran; Richard Knight; Mark W Head
Journal:  Acta Neuropathol       Date:  2018-11-27       Impact factor: 17.088

6.  Human tonsil-derived follicular dendritic-like cells are refractory to human prion infection in vitro and traffic disease-associated prion protein to lysosomes.

Authors:  Zuzana Krejciova; Paul De Sousa; Jean Manson; James W Ironside; Mark W Head
Journal:  Am J Pathol       Date:  2013-11-01       Impact factor: 4.307

7.  Uptake and degradation of protease-sensitive and -resistant forms of abnormal human prion protein aggregates by human astrocytes.

Authors:  Young Pyo Choi; Mark W Head; James W Ironside; Suzette A Priola
Journal:  Am J Pathol       Date:  2014-09-30       Impact factor: 4.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.